AU6093296A - Infectious dengue 2 virus pdk-53 as quadravalent vaccine - Google Patents

Infectious dengue 2 virus pdk-53 as quadravalent vaccine

Info

Publication number
AU6093296A
AU6093296A AU60932/96A AU6093296A AU6093296A AU 6093296 A AU6093296 A AU 6093296A AU 60932/96 A AU60932/96 A AU 60932/96A AU 6093296 A AU6093296 A AU 6093296A AU 6093296 A AU6093296 A AU 6093296A
Authority
AU
Australia
Prior art keywords
infectious dengue
quadravalent
vaccine
pdk
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60932/96A
Inventor
Natth Bhamarapravati
Siritorn Butrapet
Jeffrey Chang
Duane J. Gubler
Scott B. Halstead
Richard Kinney
Dennis W. Trent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mahidol University
US Department of Health and Human Services
Original Assignee
Mahidol University
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahidol University, US Department of Health and Human Services filed Critical Mahidol University
Publication of AU6093296A publication Critical patent/AU6093296A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU60932/96A 1995-06-07 1996-06-06 Infectious dengue 2 virus pdk-53 as quadravalent vaccine Abandoned AU6093296A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48329295A 1995-06-07 1995-06-07
US483292 1995-06-07
PCT/US1996/009209 WO1996040933A1 (en) 1995-06-07 1996-06-06 Infectious dengue 2 virus pdk-53 as quadravalent vaccine

Publications (1)

Publication Number Publication Date
AU6093296A true AU6093296A (en) 1996-12-30

Family

ID=23919500

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60932/96A Abandoned AU6093296A (en) 1995-06-07 1996-06-06 Infectious dengue 2 virus pdk-53 as quadravalent vaccine

Country Status (2)

Country Link
AU (1) AU6093296A (en)
WO (1) WO1996040933A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22683A1 (en) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri EPITHES OF THE PRE-M / M PROTEIN OF THE DENGUE VIRUS, SYNTHETIC PEPTIDES, CHEMICAL PROTEINS AND THEIR USES
EP1021545A2 (en) * 1997-09-23 2000-07-26 Bavarian Nordic Research Institute A/S Dengue virus antigens and treatment of dengue fever
US5968732A (en) 1997-12-31 1999-10-19 Akzo Nobel, N.V. Isothermal transcription based assay for the detection and genotyping of dengue virus
AU4040200A (en) * 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
AU779280B2 (en) * 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
AU2015213355B2 (en) * 2000-02-16 2017-10-05 Mahidol University Avirulent, immunogenic flavivirus chimeras
CA2398872C (en) 2000-02-16 2018-03-20 Richard M. Kinney Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (en) * 2000-05-30 2001-12-05 Aventis Pasteur Composition vaccinale
EP1159968B1 (en) * 2000-05-30 2008-10-29 Mahidol University Attenuated strains of Dengue virus and their use in a vaccine composition
US7041255B2 (en) * 2001-03-01 2006-05-09 National Health Research Institute Detection of dengue virus
CN101238144B (en) 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 Dengue serotype 1 attenuated strain
KR101582163B1 (en) * 2005-06-17 2016-01-05 사노피 파스퇴르 Dengue serotype 2 attenuated strain
FR2906724B1 (en) 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
CN105944095B (en) 2008-03-05 2021-04-02 赛诺菲巴斯德有限公司 A method of stabilizing an adjuvanted vaccine composition
AU2009241354B2 (en) 2008-04-30 2014-06-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric West Nile/Dengue viruses
EP2143440A1 (en) 2008-07-09 2010-01-13 Sanofi Pasteur Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
CN104812407B (en) 2012-07-24 2022-11-22 赛诺菲巴斯德有限公司 Vaccine composition
SG11201500439RA (en) 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
SG10201913387XA (en) 2013-03-15 2020-02-27 Takeda Vaccines Inc Compositions and methods for dengue virus chimeric constructs in vaccines
CN105246506A (en) 2013-06-21 2016-01-13 默沙东公司 Dengue virus vaccine compositions and methods of use thereof
MX2017008342A (en) 2014-12-22 2017-10-24 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof.
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur Compositions for booster vaccination against dengu
EP4082568A1 (en) 2018-09-05 2022-11-02 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
CN111944104B (en) * 2020-08-11 2022-06-21 华南师范大学 Porous double-template molecularly imprinted polymer microsphere for detecting dengue NS1 protein and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
WO1992003161A1 (en) * 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
DE69231570T2 (en) * 1991-09-19 2001-06-21 Us Health Chimeras and / or growth-inhibited flaviviruses
GB9209243D0 (en) * 1992-04-29 1992-06-17 Univ Singapore Dengue virus

Also Published As

Publication number Publication date
WO1996040933A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
AU6093296A (en) Infectious dengue 2 virus pdk-53 as quadravalent vaccine
AU4878096A (en) Hepatitis b vaccine
AU6304996A (en) Vaccines against hepatitis c
AU2550995A (en) Hepatitis c virus asialoglycoproteins
AU1308495A (en) Influenza vaccine
AU3434393A (en) Targeted virus
HUP0103908A3 (en) Novel infulenza virus vaccine composition
AU2064297A (en) Hepatitis c virus ribozymes
AU5726694A (en) Human immunodeficiency virus decoy
AP9400621A0 (en) Influenza vaccine compositions
AU4450093A (en) Hepatitis A virus vaccine
GB9420146D0 (en) Papillomavirus vaccine
AU5679394A (en) Hepatitis b virus vaccines
AU7465696A (en) Synthetic vaccine for protection against human immunodeficiency virus infection
AU4450696A (en) Enhanced immunogenic vaccine
AU6715094A (en) Recombinant vaccine
AU4554899A (en) Novel hepatitis c virus peptides and uses thereof
AU5836390A (en) Human lymphoma-associated virus
AU2961195A (en) Chicken infectious anemia virus vaccine
AU3232995A (en) Hepatitis a virus deletion mutants and vaccine formulations containing the same
AU1194997A (en) Plasmid vaccine against pseudorabies virus
AU2775692A (en) Recombinant influenza virus vaccine compositions
AU630186B2 (en) Canine corona virus vaccine
AU7336296A (en) Human hepatitis b virus dna
AU5520796A (en) Peptide-based vaccine against papillomavirus infection